Other

Labopharm Inc.

Paladin Labs Inc.

Paladin Labs (barbados) Inc.

Paladin Labs Europe Limited

Labopharm Europe Limited

Labopharm (barbados) Limited

Vincent Lenaerts

Damon Smith

Sonia Gervais

Miloud Rahmouni

Mircea Alexandru Mateescu

Pompilia Ispas-Szabo

Francois Chouinard

Rachid Ouzerourou

Johnatan Bacon

Patricia Laure Ouadji-Njiki

Patricia Laure Ouadji-Nijki

Jonathan Bacon

Rachid Ouzérourou

Roland Herwig Friedrich Beck

Elsie Van Bogaert

Reiner H&ouml;pcke

Cyril D&eacute;s&eacute;vaux

A solid dosage formulation having a core with a pharmacological agent dispersed in a first controlled-release matrix from which release of the agent is relatively slow; and a coat formed over the core and having the agent dispersed in a second controlled-release matrix from which release of the agent is relatively fast. The first matrix can be a cross-linked high amylose starch and the second matrix can be a mixture of polyvinyl acetate and polyvinylpyrrolidone.

Controlled-release compositions

A sustained-release tramadol formulation oral administration is provided which, upon initial administration of one dose, provides an analgesic effect within 2 hours, which analgesic effect continues for at least 24 hours after administration.

Sustained-release tramadol formulations with 24-hour efficacy

The present invention relates to a novel form of cross-linked high amylose starch and processes for its manufacture. Such cross-linked high amylose starch is useful as an excipient in a controlled-release pharmaceutical formulation when compressed with pharmaceutical agent(s) in a tablet. Such cross-linked high amylose starch is prepared by (a) cross-linking and chemical modification of high amylose starch, (b) gelatinization, and (c) drying to obtain a powder of said controlled release excipient. In a preferred embodiment, such cross-linked high amylose starch is prepared in the following steps: (1) granular cross-linking and additional chemical modification (e.g., hydroxypropylation) of high-amylose starch; (2) thermal gelatinization of the starch from step (1); and (3) drying the starch from step (2) to yield a powder capable of being used as a controlled release excipient.

Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture

The present invention relates to a solid slow release oral pharmaceutical dosage unit resistant to amylase which comprises a solid dosage unit made up of an admixture of a therapeutic dosage of an orally effective pharmaceutical agent, an optional polysaccharide or polyol, and high amylose starch, wherein the cross-linking of the high amylose starch has been carried out with a cross-linking agent with from about 0.1 g to about 40 g of cross-linking agent per 100 g of high amylose starch. In a preferred embodiment of the invention, the high amylose starch is modified with a functional group-attaching reagent that covalently bonds functional groups thereto.

Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents

The present invention is concerned with a solid slow release oral pharmaceutical dosage unit resistant to amylase which comprises a solid dosage unit made up of an admixture of a therapeutic dosage of an orally effective pharmaceutical product, an optional polysaccharide or polyol, and cross-linked high amylose starch, wherein the cross-linking of the high amylose starch has been carried out with a covalent or non-covalent cross-linking agent with from about 0.1 g to about 30 g of cross-linking agent per 100 g of high amylose starch.

Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds

Growing community of inventors

Slough, United Kingdom

Vincent Lenaerts